abstract |
The present invention relates to monoclonal antibody H33, or an angiogenesis inhibiting molecule that is a fragment or derivative thereof, its use in the treatment of cancer, particularly in the treatment of solid tumors, and therapeutic and diagnostic compositions containing them. The invention particularly relates to humanized derivatives of H33 or human monoclonal antibodies having the specificity of H33. |